None
Conditions
Interventions
Exposure Group:None
Non-Exposed Group:None
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age >=18 years and <=65 years; 2.Patients scheduled to undergo elective surgery at our hospital (including spinal surgery, gynecological hysterectomy, laparoscopic gastrocolic surgery, hip/knee arthroplasty, thoracoscopic lung surgery); 3.Patients routinely administered either Fumarate Targilidine Injection (exposed group) or Sufentanil Citrate Injection (non-exposed group) for postoperative analgesia; 4.Availability of complete and traceable clinical data (including surgical records, pain score records, medication records, adverse event records, and laboratory test results).
Exclusion criteria
Exclusion criteria: 1.Known allergy or hypersensitivity to Fumarate Targilidine, Sufentanil, or any excipients of their formulations; 2.Severe hepatic or renal insufficiency (Child-Pugh Class C or end-stage renal disease with CrCl <=30 mL/min); 3.Presence of severe cardiovascular diseases (e.g., uncontrolled grade 3 hypertension, severe arrhythmia, severe valvular heart disease); 4.Concurrent use of drugs with clinically significant interactions with the study medications (e.g., Sufentanil with potent central nervous system depressants, Targilidine with potent CYP3A inhibitors); 5.Pregnancy or lactation; 6.Psychiatric disorders or cognitive impairment that would impede cooperation with pain assessment; 7.Concurrent participation in any other clinical trial of postoperative analgesia; 8.Contraindications to Sufentanil use (e.g., myasthenia gravis, acute porphyria).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the Numeric Rating Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse reactions;Discontinuation rate caused by adverse reactions;The first press of PICA and total time of pressing;Sever adverse reactions and incidence rate;Postoperative Sleeping Score;SPID24/SPID48 after moving;Use rate and dosage of rescue analgesics;the total consumption of PICA;SPID 48h at resting stage;Patient satisfaction with pain management; | — |
Countries
China
Contacts
Public ContactJialin Sun
The Affiliated Hospital of Qingdao University
Outcome results
None listed